Which statement best describes the role of heparin in coagulation?

Which statement best describes the role of heparin in coagulation?

• A. Accelerates formation of Anti-thrombin III, inactivates thrombin, and prevents the conversion of fibrinogen into fibrin.
• B. Directly inhibits platelet aggregation by blocking ADP receptors.
• C. Increases production of fibrinogen by liver.
• D. Inhibits factor VIII in the coagulation cascade.

Answer: (A)

Heparin works by boosting the body's natural anticoagulant, antithrombin III. When heparin binds to antithrombin III, it dramatically increases antithrombin III’s ability to inhibit key enzymes in the coagulation cascade, especially thrombin (factor IIa) and, to a large extent, factor Xa. With thrombin inhibited, the conversion of fibrinogen to fibrin is greatly reduced, so clot formation is slowed or halted. This rapid anticoagulant effect is why heparin is used when quick anticoagulation is needed. This option is best because it directly describes the enhancement of antithrombin III activity and the downstream inactivation of thrombin, preventing fibrin formation. The other ideas don’t reflect heparin’s mechanism: it doesn’t directly block platelet aggregation (that’s more for antiplatelet drugs), it doesn’t increase liver production of fibrinogen, and its primary action isn’t to inhibit factor VIII. (Note: low-molecular-weight heparin mainly inhibits factor Xa with less effect on thrombin, differing slightly from unfractionated heparin.)

Heparin works by boosting the body's natural anticoagulant, antithrombin III. When heparin binds to antithrombin III, it dramatically increases antithrombin III’s ability to inhibit key enzymes in the coagulation cascade, especially thrombin (factor IIa) and, to a large extent, factor Xa. With thrombin inhibited, the conversion of fibrinogen to fibrin is greatly reduced, so clot formation is slowed or halted. This rapid anticoagulant effect is why heparin is used when quick anticoagulation is needed.

This option is best because it directly describes the enhancement of antithrombin III activity and the downstream inactivation of thrombin, preventing fibrin formation. The other ideas don’t reflect heparin’s mechanism: it doesn’t directly block platelet aggregation (that’s more for antiplatelet drugs), it doesn’t increase liver production of fibrinogen, and its primary action isn’t to inhibit factor VIII. (Note: low-molecular-weight heparin mainly inhibits factor Xa with less effect on thrombin, differing slightly from unfractionated heparin.)